Mode of action of ifosfamide - New aspects

Onkologie

Volumn 21, Issue SUPPL. 2, 1998, Pages 1-4

  Wagner, T ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Ifosfamide; Metabolism; Mode of action

Indexed keywords

IFOSFAMIDE;

ANTINEOPLASTIC ACTIVITY; CONFERENCE PAPER; CROSS RESISTANCE; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; HUMAN; LEUKEMIA; NEPHROTOXICITY; NEUROTOXICITY; SOLID TUMOR; STEM CELL;

EID: 0031834637     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054960     Document Type: Conference Paper

References (11)

1. Bruggemann SK, Kisro J, Wagner, T: Ifosfamide cytotoxicity on human tumor and renal cells. Role of chloroacetaldehyde in comparison to 4-Hydroxy-ifosfamide. Cancer Res 1997;57:2676-2580.
2. Wagner T: Ifosfamide clinical pharmacokinetics. Clin Pharmacokinet 1994; 26:439-456.
3. Sutherland HJ, Blair A, Zapf RW. Characterization of a hierachy in human acute myloid leukemia progenitor cell. Blood 1996;87:4754-4761.
4. Lind MJ, McGown AT, Hadfield JA, Thatcher N, Crowther D, Fox BW: The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 1989;38:1835-1840.
5. Meier T, Allenbacher A, Mueller E, Multhoff G, Botzler, C Wiesnet M, Issels R: Ifosfamide-induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anticancer Drugs 1994;5:403-409.
6. Spengler SJ, Singer B: Formation of interstrand crosslinks in chloroacetaldehyde treated DNA demonstrated by ethidium bromide flurescence Cancer Res 1988;48:4804-4806.
7. Kandala JC, Mrema JE, DeAngelo A, Daniel FB, Guntaka RV: 2-Chloroacetaldehyde and 2-chloroacetal are potent inhibitors of DNA synthesis in animal cells. Biochem Biophys Res Commun 1990; 167:457-463
8. Sood C, O'Brien PJ: Molecular mechanisms of chloroactealdehyde-induced cytotoxicity in isolated rat hepatocytes. Biochem Pharmacol 1993;46:1621-1626.
9. Brade WP, Herdrich K, Varini M. Ifosfamide pharmacology, safety and therapeutic potential. Semin Oncol 1982;9:14-23.
10. Bramwell VH, Mouridsen HT, Santoro A, Blackledge G, Somers R, Verwey J, Dombernowsky P, Onsrud P, Thomas D, Sylvester R, vanOosterom A: Cyclophosphamide versus ifosfamide: Final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol 1986;23:311-321
11. Rodiquez V, McCredie KB, Keating MJ, Valdirieso M, Bodey GP, Freireid EJ: Ifosfamide therapy for hematological malignancies in patients refractory to prior treatment. Cancer Treat Rep 1978;62:493-497.